메뉴 건너뛰기




Volumn 27, Issue 1, 2005, Pages 25-30

A simple and sensitive fully validated HPLC-UV method for the determination of 5-fluorouracil and its metabolite 5,6-dihydrofluorouracil in plasma

Author keywords

5,6 dihydrofluorouracil; 5 fluorouracil; HPLC; Plasma

Indexed keywords

DIHYDROFLUOROURACIL; FLUOROURACIL;

EID: 13244249504     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200502000-00006     Document Type: Article
Times cited : (39)

References (26)
  • 1
    • 0033770342 scopus 로고    scopus 로고
    • 5-Fluorouracil: Forty-plus and still ticking. A review of its preclinical and clinical development
    • Grem JL. 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Invest New Drugs. 2000;18:299-313.
    • (2000) Invest New Drugs , vol.18 , pp. 299-313
    • Grem, J.L.1
  • 2
    • 0031788356 scopus 로고    scopus 로고
    • Infusional 5-FU: Historical evolution, rationale, end clinical experience
    • Lokich J. Infusional 5-FU: Historical evolution, rationale, end clinical experience. Oncology. 1998;12:19-22.
    • (1998) Oncology , vol.12 , pp. 19-22
    • Lokich, J.1
  • 3
    • 0024164649 scopus 로고
    • Fluorouracil: Biochemistry and pharmacology
    • Pinedo HM, Peters GFJ. Fluorouracil: Biochemistry and pharmacology. J Clin Oncol 1988;6:1653-1664.
    • (1988) J Clin Oncol , vol.6 , pp. 1653-1664
    • Pinedo, H.M.1    Peters, G.F.J.2
  • 4
    • 0023187085 scopus 로고
    • Clinical pharmacokinetics of 5-fluorouracil and its main metabolites in plasma, urine and bile
    • Heggie GD, Sommadossi JP, Cross DS, et al. Clinical pharmacokinetics of 5-fluorouracil and its main metabolites in plasma, urine and bile. Cancer Res. 1987;47:2203-2206.
    • (1987) Cancer Res , vol.47 , pp. 2203-2206
    • Heggie, G.D.1    Sommadossi, J.P.2    Cross, D.S.3
  • 5
    • 0032978473 scopus 로고    scopus 로고
    • Can pharmacokinetic monitoring improve clinical use of fluorouracil
    • Young AM, Daryanani S, Kerr DJ. Can pharmacokinetic monitoring improve clinical use of fluorouracil. Clin Pharmacokinet. 1999;36:391-398.
    • (1999) Clin Pharmacokinet , vol.36 , pp. 391-398
    • Young, A.M.1    Daryanani, S.2    Kerr, D.J.3
  • 6
    • 0033028272 scopus 로고    scopus 로고
    • Therapeutic drug monitoring of antimetabolic cytotoxic drugs
    • Lennard L. Therapeutic drug monitoring of antimetabolic cytotoxic drugs. Br J Clin Pharmacol. 1999;47:131-143.
    • (1999) Br J Clin Pharmacol , vol.47 , pp. 131-143
    • Lennard, L.1
  • 7
    • 0033870677 scopus 로고    scopus 로고
    • Comparative pharmacokinetic analysis of 5-Fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients
    • Bocci G, Danesi R, Di Paolo A, et al. Comparative pharmacokinetic analysis of 5-Fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients. Clin Cancer Res. 2000;6:3032-3037.
    • (2000) Clin Cancer Res , vol.6 , pp. 3032-3037
    • Bocci, G.1    Danesi, R.2    Di Paolo, A.3
  • 8
    • 0034488052 scopus 로고    scopus 로고
    • Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: Identification of new mutations in the DPD gene
    • Van Kuilenburg AB, Haasjes J, Richel DJ, et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res. 2000;6:4705-4712.
    • (2000) Clin Cancer Res , vol.6 , pp. 4705-4712
    • Van Kuilenburg, A.B.1    Haasjes, J.2    Richel, D.J.3
  • 9
    • 0034050905 scopus 로고    scopus 로고
    • Known variant DPYD alleles do not explain DPD deficiency in cancer patients
    • Collie-Duguid ES, Etienne MC, Milano G, et al. Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics. 2000;10:217-223.
    • (2000) Pharmacogenetics , vol.10 , pp. 217-223
    • Collie-Duguid, E.S.1    Etienne, M.C.2    Milano, G.3
  • 10
    • 0029830640 scopus 로고    scopus 로고
    • Individualizing therapy with 5-fluorouracil related to dihydropyrimidine dehydrogenase: Theory and limits
    • Milano G, Etienne MC. Individualizing therapy with 5-fluorouracil related to dihydropyrimidine dehydrogenase: theory and limits. Ther Drug Monit. 1996;18:335-340.
    • (1996) Ther Drug Monit , vol.18 , pp. 335-340
    • Milano, G.1    Etienne, M.C.2
  • 11
    • 0037041639 scopus 로고    scopus 로고
    • Recuced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene
    • Maring JG, van Kuilenburg AB, Haasjes J, et al. Recuced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene. Br J Cancer. 2002;86:1028-1033.
    • (2002) Br J Cancer , vol.86 , pp. 1028-1033
    • Maring, J.G.1    Van Kuilenburg, A.B.2    Haasjes, J.3
  • 12
    • 0026753035 scopus 로고
    • Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients
    • Fleming A, Milano G, Thyss A, et al. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res. 1992;52:2899-2902.
    • (1992) Cancer Res , vol.52 , pp. 2899-2902
    • Fleming, A.1    Milano, G.2    Thyss, A.3
  • 13
    • 0034782963 scopus 로고    scopus 로고
    • Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients
    • Di Paolo A, Danesi R, Falcone A, et al. Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients. Ann Oncol. 2001;12:1301-1306.
    • (2001) Ann Oncol , vol.12 , pp. 1301-1306
    • Di Paolo, A.1    Danesi, R.2    Falcone, A.3
  • 14
    • 0036785124 scopus 로고    scopus 로고
    • Relationship between plasma concentrations of 5-fluorouracil and 5-fluoro-5,6-dihydrouracil and toxicity of 5-fluorouracil infusions in cancer patients
    • Di Paolo A, Ibrahim T, Danesi R, et al. Relationship between plasma concentrations of 5-fluorouracil and 5-fluoro-5,6-dihydrouracil and toxicity of 5-fluorouracil infusions in cancer patients. Ther Drug Monit. 2002;24:588-593.
    • (2002) Ther Drug Monit , vol.24 , pp. 588-593
    • Di Paolo, A.1    Ibrahim, T.2    Danesi, R.3
  • 15
    • 0024512054 scopus 로고
    • 5-FU therapeutic monitoring with dose adjustment leads to an inproved therapeutic index in head and neck cancer
    • Santini J, Milano G, Thyss A, et al. 5-FU therapeutic monitoring with dose adjustment leads to an inproved therapeutic index in head and neck cancer. Br J Cancer. 1989;59:287-290.
    • (1989) Br J Cancer , vol.59 , pp. 287-290
    • Santini, J.1    Milano, G.2    Thyss, A.3
  • 16
    • 0028357629 scopus 로고
    • Relationship between fluorouracil systemic exposure and tumor response and patient survival
    • Milano G, Etienne MC, Renee N, et al. Relationship between fluorouracil systemic exposure and tumor response and patient survival. J Clin Oncol. 1994;12:1291-1295.
    • (1994) J Clin Oncol , vol.12 , pp. 1291-1295
    • Milano, G.1    Etienne, M.C.2    Renee, N.3
  • 17
    • 0031106817 scopus 로고    scopus 로고
    • Simultaneous determination of DHFU and 5-fluorouracil in plasma by high-performance liquid chromatography
    • Ackland SP, Garg MB, Dunstan RH. Simultaneous determination of DHFU and 5-fluorouracil in plasma by high-performance liquid chromatography. Anal Biochem. 1997;246:79-85.
    • (1997) Anal Biochem , vol.246 , pp. 79-85
    • Ackland, S.P.1    Garg, M.B.2    Dunstan, R.H.3
  • 18
    • 0035950466 scopus 로고    scopus 로고
    • High-performance liquid chromatography assay with ultraviolet detection for quantification of dihydrofluorouracil in human lymphocytes: Application to measurment of dihydropyrimidine dehydrogenase activity
    • Déporte-Féty A, Picot M, Amiand M, et al. High-performance liquid chromatography assay with ultraviolet detection for quantification of dihydrofluorouracil in human lymphocytes: application to measurment of dihydropyrimidine dehydrogenase activity. J Chromatogr B. 2001;762:203-209.
    • (2001) J Chromatogr B , vol.762 , pp. 203-209
    • Déporte-Féty, A.1    Picot, M.2    Amiand, M.3
  • 19
    • 0028334435 scopus 로고
    • Determination of the concentrations of 5-fluorouracil and its metabolites in rabbit plasma and tissues by high-performance liquid chromatography
    • Del Nozal MJ, Bernal JL, Pampliega A, et al. Determination of the concentrations of 5-fluorouracil and its metabolites in rabbit plasma and tissues by high-performance liquid chromatography. J Chromatogr B. 1994;656:397-405.
    • (1994) J Chromatogr B , vol.656 , pp. 397-405
    • Del Nozal, M.J.1    Bernal, J.L.2    Pampliega, A.3
  • 20
    • 0021022886 scopus 로고
    • A gas chromatographic assay for the determination of 5,6- dihydrofluorouracil and 5-fluorouracil in human plasma
    • De Bruijn EA, Driessen O, van den Bosch N, et al. A gas chromatographic assay for the determination of 5,6-dihydrofluorouracil and 5-fluorouracil in human plasma. J Chromatagr B. 1983;278:283-289.
    • (1983) J Chromatagr B , vol.278 , pp. 283-289
    • De Bruijn, E.A.1    Driessen, O.2    Van Den Bosch, N.3
  • 21
    • 0036808430 scopus 로고    scopus 로고
    • Simultaneous HPLC determination of 5-fluorouracil and its metabolites in plasma of cancer patients
    • Casale F, Canaparo R, Muntoni E, et al. Simultaneous HPLC determination of 5-fluorouracil and its metabolites in plasma of cancer patients. Biomed Chromatogr. 2002;16:446-452.
    • (2002) Biomed Chromatogr , vol.16 , pp. 446-452
    • Casale, F.1    Canaparo, R.2    Muntoni, E.3
  • 22
    • 84988175795 scopus 로고
    • Analytical methods validation: Bioavailability, bioequivalence, and pharmacokinetic studies
    • Shah VP, Midha KK, Dighe S, et al. Analytical methods validation: bioavailability, bioequivalence, and pharmacokinetic studies. J Pharm Sci. 1992;81:309-312.
    • (1992) J Pharm Sci , vol.81 , pp. 309-312
    • Shah, V.P.1    Midha, K.K.2    Dighe, S.3
  • 23
    • 0032754717 scopus 로고    scopus 로고
    • Determination of 5-fluorouracil in microvolumes of human plasma by solvent extraction and high-performance liquid chromatography
    • Loos WJ, de Bruijn P, van Zuylen L, et al. Determination of 5-fluorouracil in microvolumes of human plasma by solvent extraction and high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 1999;735:293-297.
    • (1999) J Chromatogr B Biomed Sci Appl , vol.735 , pp. 293-297
    • Loos, W.J.1    De Bruijn, P.2    Van Zuylen, L.3
  • 24
    • 0023473360 scopus 로고
    • The stability of 5,6-dihydrofluorouracil in plasma and the consequences for its analysis
    • Van den Bosch N, Driessen O, Van der Velde EA, et al. The stability of 5,6-dihydrofluorouracil in plasma and the consequences for its analysis. Ther Drug Monit. 1987;9:443-447.
    • (1987) Ther Drug Monit , vol.9 , pp. 443-447
    • Van Den Bosch, N.1    Driessen, O.2    Van Der Velde, E.A.3
  • 25
    • 0037328454 scopus 로고    scopus 로고
    • Extensive hepatic replacement due to liver metastases has no effect on 5-fluorouracil pharmacokinetics
    • Maring JG, Piersma H, Van Dalen A, et al. Extensive hepatic replacement due to liver metastases has no effect on 5-fluorouracil pharmacokinetics. Cancer Chemother Pharmacol. 2003;51:167-173.
    • (2003) Cancer Chemother Pharmacol , vol.51 , pp. 167-173
    • Maring, J.G.1    Piersma, H.2    Van Dalen, A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.